XNAS
SCNI
Market cap0kUSD
Oct 08, Last price
1.21USD
1D
7.08%
1Q
-51.74%
Jan 2017
-99.96%
IPO
-99.97%
Name
BiondVax Pharmaceuticals Ltd
Chart & performance
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
16.07%
Rev. gr., 5y
%
Revenues
1m
+99.24%
Net income
-8m
L
CFO
-6m
L-4.80%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic licensing and collaboration agreements with prominent scientific institutions, notably the Max Planck Society and the University Medical Center Göttingen. These partnerships are geared towards the advancement and commercialization of nanosized antibodies (NanoAbs), including a specific candidate for COVID-19, and extending this technology to address various other disease indications. Founded in 2003, BiondVax maintains its corporate headquarters in Jerusalem, Israel.
Key people
Chairman of the Board · since 2019
Chief Financial Officer · since 2007
Tamar Ben-Yedidia
Chief Scientific Officer · since 2004
Internal Auditor · since 2014
Ron Babecoff
Chief Executive Officer, President, Director · since 2003
George H. Lowell
Director · since 2008
Jack Rosen
Director · since 2013
External Director · since 2008
Independent Director
Headquarters & legal address
14 EINSTEIN STREET
NESS ZIONA, M 74036
IL
NESS ZIONA, M 74036
IL
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||